Sargramostim and Ipilimumab for Metastatic Melanoma

This randomized trial comparing ipilimumab with sargramostim to ipilimumab alone reports longer overall survival and lower toxicity but no difference in progression-free survival in patients with unresectable stage III or IV melanoma.

Source: JAMA Oncology - November 6, 2014 Category: Cancer & Oncology Authors: F. Stephen Hodi, MD and colleagues Tags: Featured Research JAMA Original Investigation Source Type: research